8-K: FibroGen Highlights FG-3246 Development in Prostate Cancer Treatment

FibroGen presented an update on the clinical development program for FG-3246, a novel antibody-drug conjugate targeting CD46, for metastatic castration-resistant prostate cancer (mCRPC).

Summary

• FibroGen is developing FG-3246, an antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
• FG-3246 is designed to bind to a unique epitope on CD46, which is overexpressed in prostate cancer cells, and deliver a potent anti-microtubule agent.
• Phase 1 monotherapy trials showed a median radiographic progression-free survival (rPFS) of 8.7 months in selected cohorts, a PSA decline of over 50% in 36% of patients, and an objective response rate (ORR) of 20%.
• A Phase 1b study combining FG-3246 with enzalutamide showed a preliminary median rPFS of 10.2 months and PSA declines in 71% of evaluable patients.
• The maximum tolerated dose (MTD) for FG-3246 monotherapy was determined to be 2.7 mg/kg, while the MTD for the combination with enzalutamide was 2.1 mg/kg.
• FibroGen plans to initiate a Phase 2/3 randomized, dose optimization, biomarker-driven trial comparing FG-3246 to an androgen receptor signaling inhibitor (ARSI) switch in pre-chemo mCRPC patients.
• The company is also developing a PET biomarker, PET46, to identify patients with high CD46 expression, which is estimated to be present in 50-70% of mCRPC patients.
• FibroGen has $214.7 million in cash, cash equivalents, investments, and accounts receivable as of March 31, 2024, which is expected to fund operating plans into 2026.

Sentiment

Score: 8

Explanation: The document presents positive clinical data for FG-3246, a novel drug with a clear development plan and a strong financial position. The company is targeting a significant unmet need and has a biomarker strategy to improve patient selection. The sentiment is positive, but there are still risks associated with clinical development and competition.

Positives

• FG-3246 demonstrates promising efficacy in heavily pretreated mCRPC patients, with a median rPFS of 8.7 months in monotherapy and 10.2 months in combination with enzalutamide.
• The safety profile of FG-3246 is consistent with other MMAE-based ADCs, with manageable adverse events.
• The development of PET46 as a biomarker could enable patient selection and enrichment for clinical trials, potentially improving treatment outcomes.
• FibroGen has a strong balance sheet with sufficient cash to fund operations into 2026.
• The company is pursuing an accelerated registrational path for FG-3246 in pre-chemo mCRPC.

Negatives

• The Phase 1 trials included a relatively small number of patients, which may limit the generalizability of the results.
• Some patients experienced treatment-related adverse events, including peripheral neuropathy, neutropenia, and infusion-related reactions.
• The mCRPC market is highly competitive, and the success of FG-3246 will depend on its ability to demonstrate a clinically differentiated profile.
• The development of PET46 as a biomarker is still in the exploratory phase, and its utility for patient selection needs to be confirmed.

Risks

• The clinical development of FG-3246 is subject to regulatory approvals, which may be delayed or denied.
• The success of FG-3246 will depend on its ability to demonstrate superior efficacy and safety compared to existing treatments.
• The company faces competition from other companies developing novel therapies for mCRPC.
• The development of PET46 as a biomarker may not be successful, which could impact the clinical development of FG-3246.
• The company's financial performance is subject to market conditions and other factors that may affect its ability to fund operations.

Future Outlook

FibroGen plans to initiate a Phase 2/3 randomized, dose optimization, biomarker-driven trial comparing FG-3246 to an ARSI switch in pre-chemo mCRPC patients, and is exploring the use of PET46 as a biomarker for patient selection. The company also aims to expand the use of FG-3246 into other solid tumor types.

Management Comments

• FibroGen is targeting a significant unmet medical need with FG-3246 in mCRPC.
• The company believes that FG-3246 has the potential to be a first-in-class ADC for the treatment of mCRPC.
• FibroGen is developing a CD46 biomarker diagnostic, PET46, for screening, patient selection and enrichment.
• The company is pursuing an accelerated registrational path to pre-chemo mCRPC.

Industry Context

The presentation highlights the evolving treatment landscape for mCRPC, where there is a high unmet need for therapies that extend survival in late-stage disease. The development of FG-3246 and PET46 aligns with the industry trend towards precision medicine and biomarker-driven drug development. The company is competing with other companies developing novel therapies for mCRPC, including ADCs, BiTEs, and radioligand therapies.

Comparison to Industry Standards

• The median rPFS of 8.7 months observed in the Phase 1 monotherapy trial of FG-3246 compares favorably to the rPFS of 5.5-6.5 months seen with ARSI switch and 8.0-8.5 months with chemotherapy in the mCRPC setting.
• The preliminary median rPFS of 10.2 months in the Phase 1b combination trial of FG-3246 with enzalutamide is also encouraging when compared to the rPFS of 9.5-12 months seen with targeted therapies in the post-ARSI/pre-chemo setting.
• Other investigational treatments for mCRPC, such as ARX517 (Ambrx/JNJ), AMG 509 (Amgen), DS-7300 (Daiichi Sankyo), and JANX007 (Janux), have shown varying levels of efficacy and safety in clinical trials, with PSA50 response rates ranging from 21% to 83% and rPFS ranging from 4.8 months to not reported.
• The company is aiming for a rPFS of >10 months with FG-3246 in the Phase 2/3 trial, which would be competitive with other targeted therapies in the mCRPC space, such as 177Lu-PSMA-617 which has shown a rPFS of 9.5-12 months.

Stakeholder Impact

• Shareholders: The positive clinical data and development plan for FG-3246 could lead to increased shareholder value.
• Patients: FG-3246 has the potential to provide a new treatment option for mCRPC patients, potentially improving survival and quality of life.
• Employees: The development of FG-3246 could create new job opportunities and contribute to the company's growth.
• Customers: The company's focus on precision medicine and biomarker-driven drug development could lead to more effective and personalized treatments.

Next Steps

• Initiation of a Phase 2 monotherapy dose optimization study in 2H 2024.
• Initiation of a Phase 2/3 randomized, dose optimization, biomarker-driven trial comparing FG-3246 to an ARSI switch in pre-chemo mCRPC patients.
• Exploration of the utility of PET46 and CD46 IHC for patient selection.
• Expansion of FG-3246 into other solid tumor types.
• Continued development of the PET46 biomarker diagnostic.

Key Dates

Keywords

FG-3246, mCRPC, prostate cancer, antibody-drug conjugate, ADC, CD46, PET46, biomarker, clinical trial, radiographic progression-free survival, rPFS, PSA, objective response rate, ORR, enzalutamide, MMAE